What opioid addiction costs Arkansas
Why it matters: The total average annual cost to Arkansas for each case is $551,000.
The big picture: The cost burden falls unevenly, with states in a belt stretching through Appalachia to New England typically having bigger caseloads and a higher cost per case.
Opioid use disorder cost the U.S. an estimated $4 trillion last year, per the analysis, which used 2017 figures to project 2024 net costs.
"While this is a cost to government, it's also a cost to private businesses, and the huge cost, of course, is to the individuals who have OUD," said Margaret Scott, a principal at Avalere and author of the report.
By the numbers: The projected cost of opioid use disorder in 2024 ranged from $419,527 per case in Idaho to more than $2.4 million in D.C. That covers lost productivity, health insurance costs, property lost to crime and other variables.
The cost per case totaled more than $1 million in West Virginia, Rhode Island, Ohio and Maryland.
Some of the regional variation in costs is from lost tax revenue, which varies by state. The local availability of treatment for opioid use disorder may also drive the cost, Scott said.
Zoom in: Overdose deaths from all drugs in Arkansas dropped 26% in 2024, according to CDC data.
In 2023, Arkansas Children's Hospital announced a $70 million National Center for Opioid Research and Clinical Effectiveness to be established in Little Rock with $50 million coming from opioid settlement money.
State of play: Opioid use disorder — defined as frequent opioid use and unsuccessful efforts to quit — is estimated to affect more than 6 million people in the United States.
The cumulative economic burden on patients, including years of life lost and reduced quality of life, exceeded $3 trillion in 2024, Avalere estimated.
Private businesses absorbed more than $467 billion in costs from lost productivity and health insurance costs while the federal government bore about $118 billion in Medicare and other federal insurance costs, lost taxes and criminal justice expenses.
It cost state and local governments more than $94 billion, with about $42 billion of that going toward criminal justice costs.
The Trump administration in March released its own analysis that estimated illicit opioids cost the U.S. about $2.7 trillion in 2023.
Treatment can defray the costs by more than 40% in some instances, the analysis found.
Behavioral therapy alongside long-acting injectable buprenorphine — a treatment that reduces the risk of future overdoses — generated an estimated $295,000 savings per case, the biggest cost-saver of the options Avalere analyzed.
Therapy plus methadone and therapy plus buprenorphine administered through mucous membranes like the mouth each save about $271,000. Behavioral therapy alone saves a project $144,000 per case.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
2 hours ago
- CBS News
Weiss Memorial Hospital's access to Medicare payments revoked, IDPH announced
The future of Weiss Memorial Hospital in Uptown is uncertain after the federal Department of Health and Human Services announced that it is revoking the facility's ability to receive Medicare payments. Starting on Aug. 9, Medicare won't pay Weiss for inpatient services. The move could be devastating for the safety-net hospital, which the Sun-Times reported received over half of its 2023 revenue from the program. While the notice didn't elaborate on why it deemed Weiss not "compliant" with its guidelines, the hospital's air-conditioning system failed last month, forcing dozens of patients to be transferred to its sister institution, West Suburban Hospital in Oak Park. Since then, Weiss has rendered only limited services to patients while it awaits spare parts to fix the air conditioning. In a statement, a spokesperson for the Illinois Department of Public Health said: "The Illinois Department of Public Health has been closely monitoring the situation at Weiss Memorial Hospital. As required by law, the results of our surveys of the hospital are shared with the federal Center for Medicare and Medicaid Services (CMS). CMS holds the authority to and made the decision to terminate Weiss's involvement with the Medicare program effective August 9, 2025. There is a process for reconsideration that Weiss can pursue. IDPH is committed to ensuring patient safety and quality of care at healthcare facilities in Illinois and will engage with Weiss as appropriate."
Yahoo
7 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know
Yahoo
9 hours ago
- Yahoo
China grapples with outbreak of deadly mosquito-borne virus
A significant outbreak of chikungunya, a mosquito-borne infection, is sweeping through southern China, with thousands of cases now confirmed. The city of Foshan in Guangdong province has been particularly hard-hit, with reported cases of chikungunya fever soaring to 4,014 by Friday. This marks a rapid escalation since authorities began tracking the infection just two weeks prior, according to public records from local health departments. Sun Yang, deputy director of the National Center for Disease Control and Prevention, described the outbreak as "quite severe" during a news conference in Foshan on Wednesday. The World Health Organisation states that chikungunya, transmitted by infected mosquito bites, typically causes fever and severe joint pain, though fatalities are uncommon. In response, the Chinese Center for Disease Control and Prevention has issued advisories for preventing both chikungunya and dengue fever, another mosquito-borne illness. Recommendations include using physical barriers like screen doors and mosquito nets, alongside applying repellent to exposed skin. The CDC also noted the epidemic was "imported," without disclosing its origin. The Chinese agency also called for people who have symptoms like fever, rash and joint pain to see a doctor. Shunde district in Foshan, where 90 per cent of the cases are located, is famous for its Cantonese food, and sees many visitors each year. Patients who tested positive for chikungunya fever stayed in hospital beds covered by mosquito nets, according to photos shown on state-run broadcaster CCTV. Local media reports said on Thursday that local authorities had almost doubled the number of mosquito-proof isolation beds to 7,220 to meet the growing demand. Authorities in Guangdong are urging residents to make sure there's no standing water in their homes, such as in flowerpots, coffee machines or spare bottles. The Health Commission in Foshan stated on Thursday that a fine of up to 10,000 yuan ($1,400) could be applied if violations are found. The Beijing CDC said on Tuesday that the city occasionally experiences imported cases of chikungunya fever. There are two chikungunya vaccines that have received regulatory approvals in several countries and/or have been recommended for use in populations at risk, but the vaccines are neither widely available nor in widespread use, according to WHO. China had its first chikungunya spike in 2010 with 253 cases in Dongguan, a nearby city in the same province, according to the Guangdong provincial CDC. Several cases were found in years since then, but they weren't widespread. The country's first case was imported in 1987, according to research papers and media reports.
